Literature DB >> 33947654

A Pooled Case-only Analysis of Reproductive Risk Factors and Breast Cancer Subtype Among Black Women in the Southeastern United States.

Maureen Sanderson1,2, Tuya Pal2,3, Alicia Beeghly-Fadiel2,4, Mary Kay Fadden5, Steffie-Ann Dujon5, Chrystina Clinton5, Cecilia Jimenez5, Jennifer Davis5, Mieke Fortune5, Jasmine Thompson5, Kiera Benson5, Nicholas Conley6, Sonya Reid2,4, Ann Tezak2,3, Xiao-Ou Shu2,4, Wei Zheng2,4, William J Blot2,4, Loren Lipworth2,4.   

Abstract

BACKGROUND: We investigated the association between reproductive risk factors and breast cancer subtype in Black women. On the basis of the previous literature, we hypothesized that the relative prevalence of specific breast cancer subtypes might differ according to reproductive factors.
METHODS: We conducted a pooled analysis of 2,188 (591 premenopausal, 1,597 postmenopausal) Black women with a primary diagnosis of breast cancer from four studies in the southeastern United States. Breast cancers were classified by clinical subtype. Case-only polytomous logistic regression models were used to estimate ORs and 95% confidence intervals (CI) for HER2+ and triple-negative breast cancer (TNBC) status in relation to estrogen receptor-positive (ER+)/HER2- status (referent) for reproductive risk factors.
RESULTS: Relative to women who had ER+/HER2- tumors, women who were age 19-24 years at first birth (OR, 1.78; 95% CI, 1.22-2.59) were more likely to have TNBC. Parous women were less likely to be diagnosed with HER2+ breast cancer and more likely to be diagnosed with TNBC relative to ER+/HER2- breast cancer. Postmenopausal parous women who breastfed were less likely to have TNBC [OR, 0.65 (95% CI, 0.43-0.99)].
CONCLUSIONS: This large pooled study of Black women with breast cancer revealed etiologic heterogeneity among breast cancer subtypes. IMPACT: Black parous women who do not breastfeed are more likely to be diagnosed with TNBC, which has a worse prognosis, than with ER+/HER2- breast cancer. ©2021 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33947654      PMCID: PMC8254754          DOI: 10.1158/1055-9965.EPI-20-1784

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  29 in total

1.  Oral contraceptive use and estrogen/progesterone receptor-negative breast cancer among African American women.

Authors:  Lynn Rosenberg; Deborah A Boggs; Lauren A Wise; Lucile L Adams-Campbell; Julie R Palmer
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-07-20       Impact factor: 4.254

2.  The Southern Community Cohort Study: investigating health disparities.

Authors:  Lisa B Signorello; Margaret K Hargreaves; William J Blot
Journal:  J Health Care Poor Underserved       Date:  2010-02

3.  Statistical analysis of molecular epidemiology studies employing case-series.

Authors:  C B Begg; Z F Zhang
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1994-03       Impact factor: 4.254

4.  From the Outside In: Biological Mechanisms Linking Social and Environmental Exposures to Chronic Disease and to Health Disparities.

Authors:  Susan P Bagby; Damali Martin; Stephanie T Chung; Nishadi Rajapakse
Journal:  Am J Public Health       Date:  2019-01       Impact factor: 9.308

Review 5.  Breastfeeding: uncovering barriers and offering solutions.

Authors:  Stephanie Sayres; Lisa Visentin
Journal:  Curr Opin Pediatr       Date:  2018-08       Impact factor: 2.856

6.  Epidemiology of basal-like breast cancer.

Authors:  Robert C Millikan; Beth Newman; Chiu-Kit Tse; Patricia G Moorman; Kathleen Conway; Lynn G Dressler; Lisa V Smith; Miriam H Labbok; Joseph Geradts; Jeannette T Bensen; Susan Jackson; Sarah Nyante; Chad Livasy; Lisa Carey; H Shelton Earp; Charles M Perou
Journal:  Breast Cancer Res Treat       Date:  2007-06-20       Impact factor: 4.872

7.  Breast cancer statistics, 2017, racial disparity in mortality by state.

Authors:  Carol E DeSantis; Jiemin Ma; Ann Goding Sauer; Lisa A Newman; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2017-10-03       Impact factor: 508.702

8.  Associations of hormone-related factors with breast cancer risk according to hormone receptor status among white and African American women.

Authors:  Yong Cui; Sandra L Deming-Halverson; Martha J Shrubsole; Alicia Beeghly-Fadiel; Alecia M Fair; Maureen Sanderson; Xiao-Ou Shu; Mark C Kelley; Wei Zheng
Journal:  Clin Breast Cancer       Date:  2014-06-02       Impact factor: 3.225

9.  Reproductive factors and risk of premenopausal breast cancer by age at diagnosis: are there differences before and after age 40?

Authors:  Erica T Warner; Graham A Colditz; Julie R Palmer; Ann H Partridge; Bernard A Rosner; Rulla M Tamimi
Journal:  Breast Cancer Res Treat       Date:  2013-10-18       Impact factor: 4.872

10.  Parity, lactation, and breast cancer subtypes in African American women: results from the AMBER Consortium.

Authors:  Julie R Palmer; Emma Viscidi; Melissa A Troester; Chi-Chen Hong; Pepper Schedin; Traci N Bethea; Elisa V Bandera; Virginia Borges; Craig McKinnon; Christopher A Haiman; Kathryn Lunetta; Laurence N Kolonel; Lynn Rosenberg; Andrew F Olshan; Christine B Ambrosone
Journal:  J Natl Cancer Inst       Date:  2014-09-15       Impact factor: 13.506

View more
  2 in total

1.  A pooled case-only analysis of obesity and breast cancer subtype among Black women in the southeastern United States.

Authors:  Maureen Sanderson; Loren Lipworth; Jaleesa Moore; Tuya Pal; Alicia Beeghly-Fadiel; Mary Kay Fadden; Heather M Munro; Steffie-Ann Dujon; Sonya Reid; Ann Tezak; Miaya Blasingame; Jeania Ware; William J Blot; Xiao-Ou Shu; Wei Zheng
Journal:  Cancer Causes Control       Date:  2022-01-28       Impact factor: 2.506

2.  Patterns of Physical Activity and the Role of Obesity and Comorbidities Among Long-term African American Breast Cancer Survivors.

Authors:  Katherine Busen; Maureen Sanderson; Allison D Banks; Heather Wallace; Sarah Nechuta
Journal:  J Racial Ethn Health Disparities       Date:  2022-09-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.